The World Health Organization announced its southern hemisphere influenza vaccine composition guidelines for 2027, detailing specific viral strains for egg-based, cell culture, and recombinant vaccines. Experts reviewed surveillance data from the Global Influenza Surveillance and Response System to issue the biannual update aimed at protecting against evolving seasonal threats.
Seasonal influenza drives substantial illness and hospitalizations across the globe each year. Because these viruses continually mutate, regulatory agencies and manufacturers rely on regular formula updates to keep immunizations aligned with circulating strains. Twice annually, health authorities convene to evaluate regional disease trends and choose matching candidate strains.
Strain Selections for the 2027 Southern Hemisphere Season
Following an international consultation, the agency published its specific recommendations for immunizations deployed during the upcoming southern hemisphere cycle. The formula varies depending on whether the vaccine relies on traditional egg-based production methods or alternative cell culture, recombinant protein, and nucleic acid technologies.
For egg-based inoculations, health experts selected an A/Missouri/11/2025 (H1N1)pdm09-like virus alongside an A/Darwin/1454/2025 (H3N2)-like virus. The egg-based formula also incorporates a B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus.
For cell culture-, recombinant protein-, or nucleic acid-based options, the guidance lists the same H1N1 strain paired with a distinct H3N2 variant and a different lineage representative. These alternatives require an A/Darwin/1415/2025 (H3N2)-like virus and a B/Pennsylvania/14/2025 (B/Victoria lineage)-like virus.
Surveillance Data and Global Collaboration
The updated recommendations stem from surveillance data collected between February and August 2026. During this period, influenza A(H1N1)pdm09, A(H3N2) and influenza B viruses circulated in shifting proportions worldwide. Influenza A strains predominated across most territories, though influenza B drove transmission in North America, Eastern Asia, and parts of Northern and Western Africa.
Collaborating centers and essential regulatory laboratories process these global metrics through a long-standing monitoring network. Dr Maria Van Kerhove highlighted the international framework during the announcement.
She added that the consistent exchange of virus samples and expertise allows public health agencies to issue timely formulas, bolstering defenses against emerging respiratory risks.
“The commitment of countries and laboratories to share data, viruses and expertise enables WHO to make timely vaccine recommendations, strengthening our collective ability to detect and respond to emerging influenza threats. This is global public health collaboration at its best.”
Dr Maria Van Kerhove, WHO’s Director for Epidemic and Pandemic Management
Zoonotic Threat Monitoring and Vaccine Preparedness
Beyond seasonal strains, the biannual consultation evaluates animal-borne pathogens that occasionally infect humans. These zoonotic influenza strains remain a persistent worry due to their potential to trigger widespread pandemics.
As part of their assessment, experts select new candidate vaccine viruses derived from contemporary animal strains. These candidate viruses ensure that manufacturers can rapidly pivot to mass-produce targeted defenses if an animal-origin pathogen suddenly escalates into a broader global threat.
Читайте также
